An observational study in Urothelial Cancer, sponsored by Comprehensive Cancer Center Munich (CCCM). Recruiting at 4 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.
Sponsored by Comprehensive Cancer Center Munich (CCCM) · Observational
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Peripheral Nervous System Diseases with a site in Germany — 6 open to participants now, 7 under way, 5 of them phase 3. Peripheral Nervous System Diseases · Germany.
Among the 26 studies in Peripheral Nervous System Diseases with a site in Germany, this one is the 7th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2025, is one of 12 observational ones, and was the 23rd registered.
476 studies on the registry are indexed under Peripheral Nervous System Diseases; 103 are open to participants now.
Browse Peripheral Nervous System Diseases studies →6 of the 26 studies in Peripheral Nervous System Diseases with a site in Germany are open now. Recruiting first, the newest first:
Comprehensive Cancer Center Munich (CCCM) · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
Apurano Pharmaceuticals GmbH · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 65 Peripheral Nervous System Diseases studies recruiting now, 44 (68%) set no upper age limit and 10 (15%) stop at 75 or younger; 8 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 80 is close to the median of 80 across 97 observational studies indexed under Peripheral Nervous System Diseases.
Median enrollment 226 across the 14 interventional studies, 115 across the 12 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 26 have an industry lead sponsor. The 10 most frequent:
Comprehensive Cancer Center Munich (CCCM) is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Comprehensive Cancer Center Munich (CCCM) has 2 studies filed under Peripheral Nervous System Diseases — fewer than ten, so there is no comparison to draw.
1 of the studies in Peripheral Nervous System Diseases with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06657157Comprehensive Cancer Center Munich (CCCM)Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as First Line Treatment for Metastatic or Locally Advanced Urothelial Carcinoma | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Peripheral Nervous System Diseases with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The P-EVOLUTION trial is a prospective, multicenter, non-interventional observational study aimed at investigating peripheral neuropathy in patients receiving first-line treatment for metastatic or locally advanced urothelial carcinoma with enfortumab vedotin (EV) and pembrolizumab (P). Conducted at two German university hospitals, the study will track the incidence and severity of peripheral neuropathy, its impact on quality of life, and treatment regimen adjustments due to side effects. Approximately 80 patients are expected to be enrolled over one year.
Patients meeting the eligibility criteria and are treated at the tertiary care centers LMU Munich and TUM Munich.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., Enfortumab vedotinStudies of Enfortumab vedotinEnfortumab vedotin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Incidence of peripheral neuropathy ≥ CTCAE grade 2
Incidence of peripheral neuropathy ≥ grade 2 at baseline, week 18, week 36, week 52, and at End of Treatment (defined as the administration of the last dose of EV/P) assessed by the Patient Neurotoxicity Questionnaire (PNQ)
Time frame: baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)
Change of degree of sensory, motor and/or autonomic peripheral neuropathy applying the EORTC-CIPN20 questionnaire
A higher EORTC-CIPN20 score indicates a worse degree of neuropathy.
Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)
Change of Quality of life (QoL) applying the FACT/GOG-NTX questionnaire
An higher FACT/GOG-NTX score indicates a better QoL.
Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)
Change of neuropathic pain applying the Neuropathic Pain Symptom Inventory (NPSI) questionnaire
A higher NPSI score indicates more neuropathic pain.
Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)
Change of depression based on the Allgemeine Depressionsskala (ADS)
A higher ADS value indicates higher degree of depression.
Time frame: Baseline, week 18, week 36, week 52, and End of Treatment (defined as the administration of the last dose of EV/P)
Time to onset of peripheral neuropathy ≥ CTCAE grade 2
Time frame: From the administration of the first dose of EV/P to the end of treatment (defined as the administration of the final dose of EV/P), which is expected to occur after approximately one year.
Number of dose reductions, delays or treatment discontinuation due to peripheral neuropathy or other adverse events
Time frame: From the administration of the first dose of EV/P to the end of treatment (defined as the administration of the final dose of EV/P), which is expected to occur after approximately one year.
Number of cycles of EV + P administered
Time frame: From the administration of the first dose of EV/P to the end of treatment (defined as the administration of the final dose of EV/P), which is expected to occur after approximately one year.
Change in nerve conduction studies, as measured by neurography, in the right tibial (motor) nerve
A higher nerve conduction velocity indicates a faster transmission of electrical signal along the nerve. And vice versa.
Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)
Change in nerve conduction studies, as measured by neurography, in the right sural (sensory) nerve
A higher nerve conduction velocity indicates a faster transmission of electrical signal along the nerve. And vice versa.
Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)
Changes in hand force as measured with a Martin-Vigorimeter
Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)
Changes in sensory perception using a monofilament test
Time frame: Baseline, Week 18, End of Treatment (defined as the administration of the final dose of EV/P)
Overall survival
defined as the time from administration of the first dose to date of death due to any cause
Time frame: From administration of first dose to date of death of any cause, assessed for up to 60 months
real world Progression free survival (rw-PFS)
rw-PFS, defined as the time from the administration of the first dose of EV/P to the first documented disease progression, as determined by the investigator, or to death from any cause, whichever occurs first, assessed up to 60 months.
Time frame: From administration of the first dose of EV/P to the first documented disease progression, as determined by the investigator, or to death from any cause, whichever occurs first, assessed up to 60 months.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
Of 38 observational studies under Peripheral Nervous System Diseases, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 93. This study's planned 23 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peripheral Nervous System Diseases →
Comprehensive Cancer Center Munich (CCCM)